Menu
Abera has an extensive pipeline of mucosal vaccine projects in preclinical stage.
At Abera Bioscience, we are pioneering next-generation mucosal vaccines to address some of the most pressing infectious disease challenges. Our proprietary Bera vaccine platform enables the development of highly effective and scalable vaccines designed to provide broad immune protection through mucosal immunity—the body’s first line of defense.
Abera’s vaccine delivery platform works as a plug-and-play system where known or novel antigens can be displayed onto our carrier OMV to create new effective vaccines that are cost-effective and fast to produce. Based on the BERA Vaccine Platform we have developed a extensive pipeline of mucosal vaccines. The lead candidate – Ab-01.12 – a universal nasal vaccine against pneumococcal infections is ready for clinical phase. The pipeline also include vaccine development within Pandemic Preparedness, Influenza, Chlamydia, Covid-19 and ETEC.
Pneumococcal diseases remains a leading cause of pneumonia, meningitis, and sepsis worldwide. Our innovative mucosal pneumococcal vaccine candidate aims to provide broad serotype-independent protection by targeting conserved antigens. By stimulating mucosal and systemic immunity, our approach has the potential to enhance efficacy and reduce antibiotic resistance, offering a cost-effective and scalable solution.
Read more about Pneumococcal infections and the need for a new, serotype-independent vaccine here.
The emergence of novel respiratory pathogens underscores the need for next-generation pandemic preparedness. Using our vaccine platform BERA, we can rapidly develop mucosal vaccines against evolving threats, enhancing global vaccine accessibility and enabling fast deployment in outbreak scenarios. Our platform’s adaptability positions us at the forefront of pandemic vaccine innovation and we have been awarded funding from prominent organisations like UK Vaccine Network/Innovate UK and CEPI for further development within pandemic preparedness.
Seasonal and pandemic influenza strains continue to pose a serious global health risk. Our mucosal influenza vaccine is designed to induce a strong protection in the mucosa to reduce viral load as well as a systemic response. The initial development of this candidate is supported by funding from CEPI.
Traditional injectable vaccines primarily induce systemic immunity, but many pathogens enter the body through mucosal surfaces (e.g., respiratory tract). Our mucosal vaccine technology enhances frontline immune defenses, providing stronger and longer-lasting protection while enabling needle-free delivery for greater accessibility and compliance.
Abera Bioscience is dedicated to transforming vaccine development through cutting-edge technology, strong scientific collaborations, and a focus on unmet medical needs. Our pipeline is built to address global health priorities, ensuring that our vaccines contribute to disease prevention, pandemic preparedness, and better public health outcomes.
For more information about our ongoing projects, research partnerships, and collaboration opportunities, please contact us.
Get in contact with us via the contact form or email: info@aberabio.com
Abera Bioscience is a platform and vaccine development company based on over 30 years of research in the medical, molecular and microbiological field. Abera was founded in 2012 as a spin-out from the Swedish protein production company Xbrane Bioscience.